First study of SRP-1005 in people with Huntington's disease
Tests the new drug SRP-1005 against a placebo in people with Huntington's disease.
Plain-language title generated from the registry record
Registry title: A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Key facts
- Where
- Parkville and Westmead, AustraliaSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT07536061, who can take part
Where in Australia
- Royal Melbourne HospitalParkville, AustraliaTaking people
- Westmead HospitalWestmead, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sarepta Therapeutics, Inc.
- Trial code
- NCT07536061
- Record updated
- 19 October 2026
- Original description
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
Inclusion: Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40; Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3; Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study.
Exclusion: Recent use of investigational agents or HTT-lowering therapies; Any condition that would compromise the safety or feasibility of lumbar puncture or magnetic resonance imaging (MRI); Presence of other significant neurological or systemic illnesses; Current, chronic or active human immunodeficiency virus, hepatitis B/C; Uncontrolled psychiatric illness or substance use disorders; Pregnancy or lactation; Note: Other inclusion/exclusion criteria apply.